Progressive lung cancer determined by expression profiling and transcriptional regulation

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 242-252

  Han, Namshik ^a   Dol, Zulkifli ^a   Vasieva, Olga ^b   Hyde, Russell ^b   Liloglou, Triantafillos ^b   Raji, Olaide ^b   Brambilla, Elisabeth ^c   Brambilla, Christian ^c   Martinet, Yves ^d   Sozzi, Gabriella ^e   Risch, Angela ^f   Montuenga, Luis M ^g   Brass, Andy ^a   Field, John K ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c INSTITUT ALBERT BONNIOT   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e Centeral Hospitalier Universitaire de Nancy ^*  (Italy)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cancer progression; Lung cancer; Microarray; Network analysis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; LYMPHOID ENHANCER FACTOR 1; MYC PROTEIN; PROTEIN P21; RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IRF1; TRANSCRIPTION FACTOR MAZ; TRANSCRIPTION FACTOR MEIS1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; EARLY CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MACHINE LEARNING; MALE; METASTASIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SECOND CANCER; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ADENOCARCINOMA; ALGORITHMS; ARTIFICIAL INTELLIGENCE; CARCINOMA, SQUAMOUS CELL; DATA MINING; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC NETWORKS AND PATHWAYS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; SYSTEMS BIOLOGY; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84862901136     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1421     Document Type: Article

References (52)

1. ONS: Mortality Statistics: Deaths registered in England and Wales (Series DR), 2008. 2009.
2. Tobias J and Hochhauser D: Cancer and its Management. John Wiley & Sons Ltd., 2005.
3. Field JK, Liloglou T, Niaz A, et al: EUELC project: a multicentre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. Eur Respir J 34: 1477-1486, 2009.
4. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M and Nagai K: Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients. Thorax 65: 1092-1098, 2010.
5. Harpole DH Jr, Herndon JE II, Young WG Jr, Wolfe WG and Sabiston DC Jr: Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 76: 787-796, 1995.
6. Lu Y, Lemon W, Liu PY, et al: A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3: e467, 2006.
7. Guo NL, Wan YW, Tosun K, et al: Confirmation of gene expression- based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14: 8213-8220, 2008.
8. Shedden K, Taylor JM, Enkemann SA, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827, 2008.
9. Wilkerson MD, Yin X, Hoadley KA, et al: Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 16: 4864-4875, 2010.
10. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK and Kao CH: Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. Am J Clin Oncol 23: 241-243, 2000. (Pubitemid 32428026)
11. Foa P, Fornier M, Miceli R, et al: Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 19: 3613-3618, 1999. (Pubitemid 30000228)
12. Bryant CM, Albertus DL, Kim S, et al: Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 5: e11712, 2010.
13. Vinolas N, Molina R, Galan MC, et al: Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res 18: 631-634, 1998. (Pubitemid 28174884)
14. Tamura M, Sawabata N, Kobayashi S, et al: Prognostic significance of p21 protein expression in patients with pulmonary squamous cell carcinoma following induction chemotherapy. Ann Thorac Cardiovasc Surg 13: 9-14, 2007.
15. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW and Lee H: Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res 17: 1895-1905, 2011.
16. Garcia-Yuste M, Matilla JM and Gonzalez-Aragoneses F: Neuroendocrine tumors of the lung. Curr Opin Oncol 20: 148-154, 2008. (Pubitemid 351317402)
17. Rekhtman N: Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134: 1628-1638, 2010.
18. Berger J, Hautaniemi S, Jarvinen A-K, Edgren H, Mitra S and Astola J: Optimized LOWESS normalization parameter selection for DNA microarray data. BMC Bioinformatics 5: 194, 2004.
19. Hancock D, Wilson M, Velarde G, et al: maxdLoad2 and maxdBrowse: standards-compliant tools for microarray experimental annotation, data management and dissemination. BMC Bioinformatics 6: 264, 2005.
20. Celton M, Malpertuy A, Lelandais G and de Brevern A: Comparative analysis of missing value imputation methods to improve clustering and interpretation of microarray experiments. BMC Genomics 11: 15, 2010.
21. McMaster A, Jangani M, Sommer P, et al: Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One 6: e15766, 2011.
22. Sanguinetti G, Lawrence ND and Rattray M: Probabilistic inference of transcription factor concentrations and gene-specific regulatory activities. Bioinformatics 22: 2755-2781, 2006.
23. IPA (Ingenuity® Systems, www.ingenuity.com).
24. Siu DC and Laurance M: Rapid generations of de novo biological pathways from large-scale gene expression data using the Ingenuity Pathways Analysis application. Proc Am Assoc Cancer Res 45: 756-b-, 2004.
25. Hruz T, Laule O, Szabo G, et al: Genevestigator V3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinformatics: 420747, 2008.
26. Van Lommel A, Bolle T, Fannes W and Lauweryns JM: The pulmonary neuroendocrine system: the past decade. Arch Histol Cytol 62: 1-16, 1999. (Pubitemid 29197734)
27. Travis WD: Advances in neuroendocrine lung tumors. Ann Oncol 21 (Suppl. 7): vii65-71, 2010.
28. Pelosi G, Pasini F, Sonzogni A, et al: Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer 97: 2487-2497, 2003. (Pubitemid 36542488)
29. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795, 2001. (Pubitemid 33115977)
30. Cote F, Schussler N, Boularand S, et al: Involvement of NF-Y and Sp1 in basal and cAMP-stimulated transcriptional activation of the tryptophan hydroxylase (TPH) gene in the pineal gland. J Neurochem 81: 673-685, 2002. (Pubitemid 34809297)
31. Johnston JD, Messager S, Barrett P and Hazlerigg DG: Melatonin action in the pituitary: neuroendocrine synchronizer and developmental modulator? J Neuroendocrinol 15: 405-408, 2003. (Pubitemid 36395239)
32. Mahapatra NR, Mahata M, Ghosh S, Gayen JR, O'Connor DT and Mahata SK: Molecular basis of neuroendocrine cell type-specific expression of the chromogranin B gene: crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. J Neurochem 99: 119-133, 2006. (Pubitemid 44395135)
33. Kemp DM, Lin JC and Habener JF: Regulation of Pax4 paired homeodomain gene by neuron-restrictive silencer factor. J Biol Chem 278: 35057-35062, 2003. (Pubitemid 37102267)
34. Andersen B and Rosenfeld MG: POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 22: 2-35, 2001. (Pubitemid 32187801)
35. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP and Yuan X: SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 67: 528-536, 2007. (Pubitemid 46192189)
36. Hu Y, Wang T, Stormo GD and Gordon JI: RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites. Proc Natl Acad Sci USA 101: 5559-5564, 2004. (Pubitemid 38488831)
37. Williams L and Abou-Samra A: The transcription factors SP1 and MAZ regulate expression of the parathyroid hormone/parathyroid hormone-related peptide receptor gene. J Mol Endocrinol 25: 309-319, 2000. (Pubitemid 32059304)
38. Brandt DW, Burton DW, Gazdar AF, Oie HE and Deftos LJ: All major lung cancer cell types produce parathyroid hormone-like protein: heterogeneity assessed by high performance liquid chromatography. Endocrinology 129: 2466-2470, 1991.
39. Lasa A, Carnicer MJ, Aventín A, et al: MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia 18: 1231-1237, 2004. (Pubitemid 39023133)
40. Stang MT, Armstrong M, Liu Y, Yan P and Yim JH: IRF-1 suppresses tumor formation and protects against tumor rechallenge in a murine model of breast carcinoma: the role of tumor specific immunity. J Surg Res 121: 300, 2004.
41. Nguyen DX, Chiang AC, Zhang XH-F, et al: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62, 2009.
42. Rufini A, Agostini M, Grespi F, et al: p73 in cancer. Genes Cancer 2: 491-502, 2011.
43. Nomoto S, Haruki N, Kondo M, Konishi H and Takahashi T: Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58: 1380-1383, 1998. (Pubitemid 28193594)
44. Irwin M, Marin MC, Phillips AC, et al: Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648, 2000.
45. Zaika A, Irwin M, Sansome C and Moll UM: Oncogenes induce and activate endogenous p73 protein. J Biol Chem 276: 11310-11316, 2001. (Pubitemid 38089320)
46. Concin N, Hofstetter G, Berger A, et al: Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 crosstalk in vivo. Clin Cancer Res 11: 8372-8383, 2005. (Pubitemid 41746950)
47. waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 18: 213-217, 1998.
48. Shoji T, Tanaka F, Takata T, et al: Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20: 3865-3871, 2002.
49. Komiya T, Hosono Y, Hirashima T, et al: p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 3: 1831-1835, 1997. (Pubitemid 27444724)
50. Blundell R, Harrison DJ and O'Dea S: p21(Waf1/Cip1) regulates proliferation and apoptosis in airway epithelial cells and alternative forms have altered binding activities. Exp Lung Res 30: 447-464, 2004. (Pubitemid 39096094)
51. Liu S, Bishop WR and Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6: 183-195, 2003. (Pubitemid 37129918)
52. Ocker M and Schneider-Stock R: Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374, 2007. (Pubitemid 47031035)